Interferon Alpha in Systemic Lupus Erythematosus

被引:82
|
作者
Niewold, Timothy B. [2 ,3 ]
Clark, Daniel N. [1 ]
Salloum, Rafah [2 ,3 ]
Poole, Brian D. [1 ]
机构
[1] Brigham Young Univ, Dept Mol Biol & Microbiol, Provo, UT 84602 USA
[2] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA
[3] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA
关键词
REGULATORY T-CELLS; PLASMACYTOID DENDRITIC CELLS; GENOME-WIDE ASSOCIATION; TOLL-LIKE RECEPTORS; I INTERFERON; IFN-ALPHA; RISK HAPLOTYPE; DISEASE-ACTIVITY; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASES;
D O I
10.1155/2010/948364
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The pleiotropic cytokine interferon alpha is involved in multiple aspects of lupus etiology and pathogenesis. Interferon alpha is important under normal circumstances for antiviral responses and immune activation. However, heightened levels of serum interferon alpha and expression of interferon response genes are common in lupus patients. Lupus-associated autoantibodies can drive the production of interferon alpha and heightened levels of interferon interfere with immune regulation. Several genes in the pathways leading to interferon production or signaling are associated with risk for lupus. Clinical and cellular manifestations of excess interferon alpha in lupus combined with the genetic risk factors associated with interferon make this cytokine a rare bridge between genetic risk and phenotypic effects. Interferon alpha influences the clinical picture of lupus and may represent a therapeutic target. This paper provides an overview of the cellular, genetic, and clinical aspects of interferon alpha in lupus.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Type I interferon in the pathogenesis of systemic lupus erythematosus
    Postal, Mariana
    Vivaldo, Jessica F.
    Fernandez-Ruiz, Ruth
    Paredes, Jacqueline L.
    Appenzeller, Simone
    Niewold, Timothy B.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2020, 67 : 87 - 94
  • [32] INTERFERON TREATMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE)
    YEGOROVA, ON
    BALABANOVA, RM
    [J]. TERAPEVTICHESKII ARKHIV, 1994, 66 (12): : 45 - 46
  • [33] Systemic lupus erythematosus syndrome induced by interferon therapy
    Alfaro, EM
    Rodríguez, FM
    Sancho, JJB
    Rodríguez, IT
    [J]. MEDICINA CLINICA, 2004, 123 (15): : 597 - 597
  • [34] SERUM LEVELS OF INTERFERON IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    DUDLI, C
    KAISER, V
    AGUET, M
    JOLLER, H
    PICHLER, WI
    GROB, PJ
    FONTANA, A
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1986, 116 (04) : 104 - 109
  • [36] Interferon pathway activation in systemic lupus erythematosus.
    Crow M.K.
    [J]. Current Rheumatology Reports, 2005, 7 (6) : 463 - 468
  • [37] Targeting type I interferon in systemic lupus erythematosus
    Timothy B. Niewold
    [J]. Nature Reviews Rheumatology, 2016, 12 : 377 - 378
  • [38] Systemic lupus erythematosus and the type I interferon system
    Lars Rönnblom
    Gunnar V Alm
    [J]. Arthritis Res Ther, 5
  • [39] The genetics of type I interferon in systemic lupus erythematosus
    Bronson, Paola G.
    Chaivorapol, Christina
    Ortmann, Ward
    Behrens, Timothy W.
    Graham, Robert R.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (05) : 530 - 537
  • [40] Type I Interferon Signature in Systemic Lupus Erythematosus
    Bezalel, Shira
    Guri, Keren Mahlab
    Elbirt, Daniel
    Asher, Ilan
    Sthoeger, Zev Moshe
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (04): : 246 - 249